Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8621535 | 0.90 | POLB (0.41) | POLBSLC6A4ALDH1A1LMNAMAPT | |
| SCHEMBL8622245 | 0.86 | SLC6A2 (0.48) | POLBSLC6A4ALDH1A1LMNAMAPT | |
| SCHEMBL8623419 | 0.83 | SLC6A4 (0.46) | SLC6A4SLC6A9 | |
| SCHEMBL8623402 | 0.81 | POLB (0.44) | POLBALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL8624287 | 0.78 | POLB (0.41) | POLBALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL8622068 | 0.78 | SLC6A9 (0.48) | SLC6A4SLC6A9 | |
| SCHEMBL8618661 | 0.78 | POLB (0.48) | POLBALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL8619662 | 0.78 | POLB (0.45) | POLBSLC6A4ALDH1A1LMNAMAPT | |
| SCHEMBL8620195 | 0.77 | F2 (0.39) | SLC6A4SLC6A9SLC7A5 | |
| SCHEMBL8620515 | 0.76 | POLB (0.46) | POLBALDH1A1LMNAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | disclosed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |